Theriva Biologics Ownership 2024 | Who Owns Theriva Biologics Now?

Overview RevenueFinancials Chart Transcripts

Insider Ownership

1.32%

Theriva Biologics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
BRIDGEWAY FUNDS INC	0.01%	28,528	-	-	Sep 29, 2023

Theriva Biologics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 28.53K shares, compromising 0.01% of its total assets.

Theriva Biologics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 08, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	14,000	$0.69	$9.70K	250,000
Jun 07, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	26,000	$0.63	$16.45K	236,000
Feb 13, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	25,000	$1.04	$26.07K	210,000
Feb 03, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	25,000	$0.94	$23.51K	185,000
Jan 26, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	25,000	$0.87	$21.82K	160,000
Jan 23, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	25,000	$0.75	$18.70K	135,000
Jan 03, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	100,000	$0.44	$43.70K	110,000

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 08, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	14,000	$0.69	$9.70K	250,000
Jun 07, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	26,000	$0.63	$16.45K	236,000
Feb 13, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	25,000	$1.04	$26.07K	210,000
Feb 03, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	25,000	$0.94	$23.51K	185,000
Jan 26, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	25,000	$0.87	$21.82K	160,000
Jan 23, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	25,000	$0.75	$18.70K	135,000
Jan 03, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	100,000	$0.44	$43.70K	110,000

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Dec 15, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	A-Award	Buy	700,000	$0.59	$411.25K	700,000
Dec 15, 2023	Wolf Jeffrey Alan	director	-	A-Award	Buy	110,000	$0.59	$64.63K	110,000
Dec 15, 2023	Kraws Jeffrey J	director	-	A-Award	Buy	110,000	$0.59	$64.63K	110,000
Dec 15, 2023	MONAHAN JOHN J	director	-	A-Award	Buy	110,000	$0.59	$64.63K	110,000
Jun 08, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	14,000	$0.69	$9.70K	250,000
Jun 07, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	26,000	$0.63	$16.45K	236,000
Feb 13, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	25,000	$1.04	$26.07K	210,000
Feb 03, 2023	SHALLCROSS STEVEN A	director, officer	CEO and CFO	P-Purchase	Buy	25,000	$0.94	$23.51K	185,000
Jan 26, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	25,000	$0.87	$21.82K	160,000
Jan 23, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	25,000	$0.75	$18.70K	135,000
Jan 03, 2023	SHALLCROSS STEVEN A	officer	CEO and CFO	P-Purchase	Buy	100,000	$0.44	$43.70K	110,000

The last insider buy of TOVX was made by SHALLCROSS STEVEN A on Jun 08 2023, buying 14,000 shares at $0.69 per share (worth $9.70K).

Theriva Biologics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q4 2023	4	-	-
Q2 2023	2	-	-
Q1 2023	4	-	-
Q4 2022	1	-	-

4 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Theriva Biologics's insiders, as of Q4 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q4 2023	-	-	-
Q2 2023	2	-	-
Q1 2023	4	-	-
Q4 2022	1	-	-

As of Q4 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Theriva Biologics's stocks.

Theriva Biologics Peer Ownership

Ticker	Company
GOVX	GeoVax Labs, Inc.
BDRX	Biodexa Pharmaceuticals Plc
PMVP	PMV Pharmaceuticals, Inc.
FRTX	Fresh Tracks Therapeutics, Inc.
XCUR	Exicure, Inc.
SABS	SAB Biotherapeutics, Inc.
LSTA	Lisata Therapeutics, Inc.
VRPX	Virpax Pharmaceuticals, Inc.
MRKR	Marker Therapeutics, Inc.
REVB	Revelation Biosciences, Inc.
DFFN	CervoMed Inc.
FWBI	Entero Therapeutics, Inc.
VCNX	Vaccinex, Inc.
AVTX	Avalo Therapeutics, Inc.
PRAX	Praxis Precision Medicines, Inc.
SLRX	Salarius Pharmaceuticals, Inc.
PTIX	Protagenic Therapeutics, Inc.
CBIO	Gyre Therapeutics, Inc.
LUMO	Lumos Pharma, Inc.
KTRA	Kintara Therapeutics, Inc.